Clin2
NCT06258551Possibly a fitRecruiting

Tracking hard-to-treat bacteria in ICU and transplant patients

Antimicrobial Drug ResistanceAntibiotic Resistant InfectionClostridium DifficileCarbapenem-Resistant Enterobacteriaceae InfectionExtended Spectrum Beta-Lactamase Producing Bacteria InfectionVancomycin Resistant Enterococci InfectionCarbapenem Resistant Bacterial InfectionVancomycin-Resistant Enterococcal Infection

Part of Immune system & allergy, Infections clinical trials.

This study will track how certain hard-to-treat bacteria spread and cause infections in people who are in the intensive care unit (ICU) or have had a stem cell transplant. The goal is to better understand and prevent these infections in vulnerable patients.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
1,000 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You have been admitted to an intensive care unit (ICU) or a stem cell transplant unit in the past 24 hours.
  • You are 18 years old or older.
  • You are not pregnant.
  • You do not have a history of inflammatory bowel disease (like Crohn's disease or ulcerative colitis).
  • You do not have a colostomy, ileostomy, or other gastrointestinal derivation.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07221370Recruiting· Phase 2/Phase 3
Vancomycin to prevent C. diff infection in ICU patients

This trial tests whether giving vancomycin through a tube into the stomach can prevent a serious gut infection called C. diff in people who are very sick in the ICU and taking antibiotics. If you qualify, you might receive this medicine to lower your risk.

Moreno Valley, California
NCT05922124Recruiting· Phase 4
Testing two antibiotics against resistant lung and bloodstream infections

This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.

Haifa
NCT07255443Not yet recruiting
Gut bacteria study in ICU patients

This study looks at certain drug-resistant bacteria in the gut of ICU patients. It aims to understand how common these bacteria are and may help guide future infection control efforts.

NCT07603128Recruiting
Testing a tool to predict antibiotic-resistant infections in ICU patients

This study validates a prediction tool designed to identify which ICU patients are at risk of developing multidrug-resistant gram-negative bacteria (a serious infection resistant to many antibiotics). The tool may help doctors start appropriate treatment earlier and improve patient outcomes.

Nanjing, Jiangsu
NCT05367011Not yet recruiting
Track antibiotic levels in ICU patients with sepsis

This study monitors how antibiotics behave in the body for ICU patients being treated for sepsis or septic shock. It aims to learn whether better monitoring can support safer, more effective antibiotic use.

NCT07481773Recruiting
Blood test to guide antibiotic decisions in the ICU

This trial uses a new blood test (called BV test) to help doctors decide if antibiotics should be stopped or continued for ICU patients with suspected or confirmed infections. It aims to reduce unnecessary antibiotic use while keeping patients safe.

Montreal, Quebec

Hear when a new Antimicrobial Drug Resistance trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.